To print: Select File and then Print from your browser's menu --------------------------------------------------------------------------------------- Title: Condylox Gel Approved by FDA for Genital and Perianal Warts URL: http://www.pslgroup.com/dg/2117A.htm Doctor's Guide March 17, 1997
CORONA, Calif., March 17, 1997 -- The U.S. Food and Drug Administration (FDA) has approved to market Condylox(R) Gel 0.5% (podofilox) for the treatment of external genital and perianal warts (condyloma acuminata). The product is expected to be launched in the second quarter of fiscal 1997. It is believed that Condylox(R) Gel offers two important advancements over Condylox topical solution, introducedin 1991: easy, finger-tip application and an expanded perianal wart indication. Oclassen Pharmaceuticals, Inc., a wholly-owned subsidiary of Watson Pharmaceuticals, is dedicated to the development and acquisition of unique proprietary dermatological products. Watson Pharmaceuticals, Inc., headquartered in Corona, CA, is engaged in the manufacture and sale of off-patent medications and branded pharmaceutical products. --------------------------------------------------------------------------------------------- Copyright © 1999 P\S\L Consulting Group Inc. All rights reserved. Republication or redistribution of P\S\L content is expressly prohibited without the prior written consent of P\S\L. P\S\L shall not be liable for any errors, omissions or delays in this content or any other content on its sites, newsletters or other publications, nor for any decisions or actions taken in reliance on such content. --------------------------------------------------------------------------------------------- This news story was printed from *Doctor's Guide to the Internet* located at http://www.docguide.com --------------------------------------------------------------------------------------- Return to News Story Page This site is maintained by webmaster@pslgroup.com Please contact us with any comments, problems or bugs. All contents Copyright (c) 1998 P\S\L Consulting Group Inc. All rights reserved.